View in EDS

439O - A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors.

Saved in:
Bibliographic Details
Title: 439O - A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors.
Authors: Cassier, P.1 (AUTHOR), Eberst, L.1 (AUTHOR), Garin, G.2 (AUTHOR), Courbebaisse, Y.3 (AUTHOR), Terret, C.1 (AUTHOR), Robert, M.4 (AUTHOR), Frenel, J.-S.5 (AUTHOR), Depil, S.1 (AUTHOR), Delord, J.-P.6 (AUTHOR), Perol, D.7 (AUTHOR), Ray-Coquard, I.L.1 (AUTHOR), Bidaux, A.-S.8 (AUTHOR), Tabone-Eglinger, S.9 (AUTHOR), Gilles-Afchain, L.1 (AUTHOR), Treilleux, I.10 (AUTHOR), Wang, Q.11 (AUTHOR), Ducarouge, B.12 (AUTHOR), Mehlen, P.13 (AUTHOR), Blay, J.-Y.14 (AUTHOR), Gomez-Roca, C.A.15 (AUTHOR)
Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv159-v159. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdz244.001